Alastair Hotblack

Alastair Hotblack

Auto-generated profile, based on publicly available information

Alastair Hotblack

Research Department of Hematology, Cancer Institute, University College London, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
GAGiulia Agliardi
Giulia Agliardi
ALAnna Rita Liuzzi
Anna Rita Liuzzi
AHAlastair Hotblack
Alastair Hotblack
DFDonatella De Feo
Donatella De Feo
NNNicolás Núñez
Nicolás Núñez
BBBurkhard Becher
Burkhard Becher
Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain cancer, for which effective therapies are urgently needed. Chimeric antigen receptor (CAR)-based immunotherapy represents a promising therapeutic approach, but it is often impeded by highly immunosuppressive tumor microenvironments (TME). Here, in an immunocompetent, orthotopic GBM mouse model, we show that CAR-T cells targeting tumor-specific epidermal growth factor receptor variant III (EGFRvIII) alone fail to control fully established tumors but, when combined with a single, locally delivered dose of IL-12, achieve durable anti-tumor responses. IL-12 not only boosts cytotoxicity of CAR-T cells, but also reshapes the TME, driving increased infiltration of proinflammatory CD4+ T cells, decreased numbers of regulatory T cells (Treg), and activation of the myeloid compartment. Importantly, the immunotherapy-enabling benefits of IL-12 are achieved with minimal systemic effects. Our findings thus show that local delivery of IL-12 may be an effective adjuvant for CAR-T cell therapy for GBM.